Troriluzole hydrochloride is under clinical development by Biohaven Pharmaceutical Holding Company and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Troriluzole hydrochloride’s likelihood of approval (LoA) and phase transition for Spinocerebellar Ataxia (SCA) took place on 16 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Troriluzole hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Troriluzole hydrochloride overview

Troriluzole Hydrocholride (trigriluzole, BHV-4157) is under development for the treatment of spinocerebellar ataxia, obsessive-compulsive disorder, metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, bladder cancer, classic Hodgkin lymphoma and Alzheimer's disease. The drug candidate targets glutamate neurotransmitter. It is a new chemical entity and a prodrug of riluzole (BHV-0223).

It was under development for the treatment of neuropsychiatric disorders,generalized anxiety disorder and Friedreich Ataxia.

Biohaven Pharmaceutical Holding Company overview

Biohaven Pharmaceutical Holding Company (Biohaven) is a clinical-stage biopharmaceutical company. The company develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that includes two product candidates such as rimegepant for the acute treatment of migraine, and zavegepant for the prevention of a chronic and episodic migraine. Its glutamate modulation platform includes product candidates such as trigriluzole and BHV-4157 for the treatment of obsessive-compulsive disorder (OCD) and Alzheimer’s disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS); and BHV-5000 for treating symptoms associated with Rett syndrome and other neuropsychiatric indications. Biohaven is headquartered in New Haven, Connecticut, the US.

Quick View Troriluzole hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Troriluzole hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.